| scholarly article | Q13442814 |
| P50 | author | Joseph S Solomkin | Q64029407 |
| Janis Gardovskis | Q79309972 | ||
| P2093 | author name string | David Evans | |
| Philippe Montravers | |||
| Larry Tsai | |||
| Kenneth Lawrence | |||
| Angie Sway | |||
| P2860 | cites work | Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). | Q50148742 |
| Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. | Q52695014 | ||
| Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline | Q57789735 | ||
| Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial | Q61727885 | ||
| Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone | Q72757815 | ||
| Perforated and Gangrenous Appendicitis: An Analysis of Antibiotic Failures | Q72792662 | ||
| Source control for surgical infections | Q80175127 | ||
| Intra-abdominal infections | Q83467775 | ||
| Current epidemiology, genetic evolution and clinical impact of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae | Q88296741 | ||
| Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections | Q26991886 | ||
| The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia | Q27001437 | ||
| Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis | Q27002495 | ||
| Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America | Q28268745 | ||
| The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. | Q30234957 | ||
| The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection | Q30275008 | ||
| The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data | Q30998307 | ||
| Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections | Q33622765 | ||
| A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections | Q34474973 | ||
| Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial | Q34544823 | ||
| Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). | Q35545954 | ||
| Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy | Q36150730 | ||
| Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program | Q36915096 | ||
| Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis | Q36937529 | ||
| Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. | Q38286351 | ||
| Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies? | Q38756408 | ||
| rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines. | Q38849606 | ||
| Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013. | Q39164904 | ||
| In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. | Q40135682 | ||
| Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial Resista | Q40517201 | ||
| The global epidemiology of carbapenemase-producing Enterobacteriaceae. | Q40552344 | ||
| In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. | Q40633420 | ||
| A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections | Q41634906 | ||
| Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. | Q41879631 | ||
| Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis | Q42232433 | ||
| A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections | Q42952452 | ||
| Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years | Q46300256 | ||
| From "An Enzyme Able to Destroy Penicillin" to Carbapenemases: 70 Years of Beta-lactamase Misbehaviour | Q47951222 | ||
| In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. | Q50023017 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P921 | main subject | meropenem | Q421670 |
| multicenter clinical trial | Q6934595 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 921-929 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections | |
| P478 | volume | 69 |
| Q90171597 | Antibiotics in the clinical pipeline in October 2019 |
| Q89598600 | Carbapenem-Sparing Strategies for ESBL Producers: When and How |
| Q64244026 | Eravacycline: A Review in Complicated Intra-Abdominal Infections |
| Q92070193 | FDA approved antibacterial drugs: 2018-2019 |
| Q92953652 | In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus |
| Q64911007 | The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. |
| Q91742696 | The Continuing Threat of Methicillin-Resistant Staphylococcus aureus |
| Q92856050 | The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
| Q99708918 | Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance |
| Q64108242 | Treatment of Infections Due to MDR Gram-Negative Bacteria |
Search more.